This article's lead is ready for translation. Click for more information.

Olsalazine

From WikiProjectMed
Jump to navigation Jump to search
Olsalazine
Names
Trade namesDipentum
Other namesOlsalazine sodium
Clinical data
Drug class5-ASA derivative[1]
Main usesUlcerative colitis, Crohn’s disease[1][2]
Side effectsNumbess, fast heart beat[3]
Pregnancy
category
  • AU: C[4]
  • US: C (Risk not ruled out)[4]
Routes of
use		By mouth
Typical dose500mg BID[3]
External links
AHFS/Drugs.comMonograph
MedlinePlusa601088
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetics
Protein binding99%
Elimination half-life0.9 hours
Chemical and physical data
FormulaC14H10N2O6
Molar mass302.242 g·mol−1
3D model (JSmol)
  • O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2
  • InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ checkY
  • Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N checkY

Olsalazine, sold under the brand name Dipentum among others, is a medication used to treat ulcerative colitis and Crohn’s disease.[1][2] It is used in people who cannot take sulfasalazine.[1] It is taken by mouth in the form of tablet or capsule.[3] If needed, contents of the capsule can be sprinkled on food.[3]

Side effects are uncommon but include numbess and a fast heart beat.[3] Other side effects may include diarrhea, nausea, heartburn, tiredness, and headache.[1] Caution is advised in kidney problems.[3] It is broken down into mesalazine (5-ASA) in the colon by which it acts.[2] 5-ASA than inhibits cyclooxygenase and lipoxygenase thereby reducing prostoglandin and leukotriene production.[1]

Olsalazine was approved for medical use in the United States in 1990.[1] It is available as a generic medication.[3] In the United Kingdom a months supply costs the NHS around £150 as of 2021.[3] In the United States this amount costs about 1,600 USD.[5]

Medical uses

It is used to treat ulcerative colitis and Crohn’s disease.[1][2]

Dose

In ulcerative colitis, a typical dose is 500mg twice daily after food.[3] Doses up to 3 grams per day; however, may be used.[6]


It is taken by mouth in the form of tablet or capsule.[3] If needed, the contents of the capsule can be sprinkled on food.[3]

History

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.[1]

Society and culture

Supply

The drug is supplied by UCB Pharma.

Cost

In the UK, a months supply costs the NHS around £144 for the capsule form and £160 for the tablet.[3]

Research

In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.[7]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 "Olsalazine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 7 November 2021. Archived 18 January 2021 at the Wayback Machine
  2. ↑ 2.0 2.1 2.2 2.3 "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 12 January 2021. Retrieved 9 January 2021. Archived 12 January 2021 at the Wayback Machine
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 "1. Gastro-intestinal system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 47. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
  4. ↑ 4.0 4.1 "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Archived from the original on 18 January 2021. Retrieved 9 October 2020. Archived 18 January 2021 at the Wayback Machine
  5. ↑ "Olsalazine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 7 November 2021.
  6. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 47. ISBN 978-0857114105.
  7. ↑ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Archived from the original on 25 October 2021. Retrieved 16 January 2021. Archived 25 October 2021 at the Wayback Machine

External links

External sites:
Identifiers:

Retrieved from "https://mdwiki.org/w/index.php?title=Olsalazine&oldid=1468727"